为探究 BCMA 靶向疗法治疗多发性骨髓瘤（MM）的效果，研究人员总结 2024 ASH 年会成果，为患者带来希望。 在血液疾病的领域中，多发性骨髓瘤（Multiple Myeloma，MM）一直是困扰医学界的难题。这是一种恶性浆细胞病，随着病情发展，患者的正常造血功能受到抑制 ...

Several targeting approaches are in development. BCMA is preferentially expressed on plasma cells and other mature B cells in blood 5. These cells originate with B-lymphocyte progenitors that ...

DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...

Blenrep (belantamab mafodotin) becomes the first BCMA-targeted drug for myeloma to be approved in the EU, and according to its label can be used to treat the blood cancer in adult patients who ...